Agios Shares Catch a Second Wind: Leerink's Upgrade Fuels Rebound Hopes
The Quiet Revolution: How One Pill Could Change the Game for Sickle Cell and Thalassemia Patients
Agios Shares Plummet as FDA Halts Pyrukynd's Thalassemia Review, Sending Shockwaves Through Biotech